pt en es

Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Flavopiridol [146426-40-6]

Imprimir

Referência HY-10005-5mg

Tamanho : 5mg

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Description

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

IC₅₀ & Target^[3]

CDK1/Cyc B1

30 nM (IC₅₀)

CDK2/Cyc E

170 nM (IC₅₀)

CDK4/Cyc D1

100 nM (IC₅₀)

MAP

19000 nM (IC₅₀)

PKC

14000 nM (IC₅₀)

EGFR

22000 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	0.023 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.029 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.031 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.064 μM Compound: Flavopiridol	Growth inhibition of human A2780 cells after 48 hrs by MTT assay Growth inhibition of human A2780 cells after 48 hrs by MTT assay	[PMID: 33581551]
A2780	IC₅₀	0.038 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.056 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.071 μM Compound: 1 (flavopiridol)	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay	[PMID: 15027863]
A2780	IC₅₀	0.078 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	15 μM Compound: 1 (flavopiridol)	Inhibition of A2780 cell clonogenic assay Inhibition of A2780 cell clonogenic assay	[PMID: 11063609]
A2780	IC₅₀	71 nM Compound: 1	Cytotoxic effect on human ovarian (A2780) cancer cell line Cytotoxic effect on human ovarian (A2780) cancer cell line	[PMID: 15125971]
A-431	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of A431 human squamous cell carcinoma cell proliferation Inhibition of A431 human squamous cell carcinoma cell proliferation	[PMID: 12190313]
A549	CC₅₀	>100 μM Compound: 11; L86-8275, HMR1275	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33539089]
A549	GI₅₀	0.14 μM Compound: FVP	Antiproliferative activity against human A549 cells after 3 days by SRB method Antiproliferative activity against human A549 cells after 3 days by SRB method	[PMID: 25914804]
A549	GI₅₀	0.145 μM Compound: Flavopiridol	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 33581551]
A549	IC₅₀	0.096 μM Compound: Flavopiridol	Inhibition of A549 human lung carcinoma cell proliferation Inhibition of A549 human lung carcinoma cell proliferation	[PMID: 12190313]
A549	IC₅₀	0.1 μM Compound: Flavopiridol	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
ABAE	IC₅₀	0.045 μM Compound: Flavopiridol	Inhibition of ABAE human fibroblast cell proliferation Inhibition of ABAE human fibroblast cell proliferation	[PMID: 12190313]
BJ	EC₅₀	>86.2069 μM Compound: 4	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Caco-2	IC₅₀	0.086 μM Compound: Flavopiridol	Inhibition of CACO-2 human colon carcinoma cell proliferation Inhibition of CACO-2 human colon carcinoma cell proliferation	[PMID: 12190313]
CCRF-CEM	IC₅₀	0.052 μM Compound: Flavopiridol	Inhibition of CCRF-CEM human leukemia cell proliferation Inhibition of CCRF-CEM human leukemia cell proliferation	[PMID: 12190313]
CNE-2	IC₅₀	0.12 μM Compound: Flavopiridol	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
COLO 205	EC₅₀	>20 μM Compound: Chemical Probe: Flavopiridol	Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry	[PMID: 24919854]
CWR22R	IC₅₀	0.24 μM Compound: FP	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672930]
DU-145	GI₅₀	0.15 μM Compound: FVP	Antiproliferative activity against human DU145 cells after 3 days by SRB method Antiproliferative activity against human DU145 cells after 3 days by SRB method	[PMID: 25914804]
HCT-116	EC₅₀	0.034 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs	[PMID: 27326333]
HCT-116	GI₅₀	0.056 μM Compound: Flavopiridol	Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay	[PMID: 33581551]
HCT-116	IC₅₀	0.017 μM Compound: Flavopiridol	Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.018 μM Compound: Flavopiridol	Inhibition of HCT116 human colon carcinoma cell proliferation Inhibition of HCT116 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.021 μM Compound: Flavopiridol	Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.03 μM Compound: Flavopiridol	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HCT-116	IC₅₀	13 μM Compound: 1 (flavopiridol)	Inhibition of HCT116 cell clonogenic assay Inhibition of HCT116 cell clonogenic assay	[PMID: 11063609]
HCT-116	IC₅₀	20 nM Compound: Alvocidib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
HeLa	CC₅₀	0.12 μM Compound: 8; Alvocidib	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 27171036]
HeLa	GI₅₀	0.043 μM Compound: Flavopiridol	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 33581551]
HeLa	IC₅₀	0.15 μM Compound: Flavopiridol	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HepG2	EC₅₀	0.1464 μM Compound: 4	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
HepG2	IC₅₀	0.56 μM Compound: Flavopiridol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HL-60	IC₅₀	0.046 μM Compound: Flavopiridol	Inhibition of HL60 human leukemia cell proliferation Inhibition of HL60 human leukemia cell proliferation	[PMID: 12190313]
HMEC-1	GI₅₀	0.061 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.062 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.066 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay	[PMID: 23301767]
HS27	IC₅₀	0.051 μM Compound: Flavopiridol	Inhibition of Hs 27 human fibroblast cell proliferation Inhibition of Hs 27 human fibroblast cell proliferation	[PMID: 12190313]
HT-29	GI₅₀	0.131 μM Compound: Flavopiridol	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 33581551]
K562	IC₅₀	0.13 μM Compound: Flavopiridol	Inhibition of K562 human leukemia cell proliferation Inhibition of K562 human leukemia cell proliferation	[PMID: 12190313]
K562	IC₅₀	125 nM Compound: Alvocidib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
KB	GI₅₀	0.16 μM Compound: FVP	Antiproliferative activity against human KB cells after 3 days by SRB method Antiproliferative activity against human KB cells after 3 days by SRB method	[PMID: 25914804]
KOPN-8	EC₅₀	0.1926 μM Compound: 4	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
LNCaP	IC₅₀	0.016 μM Compound: Flavopiridol	Inhibition of LNCaP human prostate carcinoma cell proliferation Inhibition of LNCaP human prostate carcinoma cell proliferation	[PMID: 12190313]
LS174T	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of LS174T human colon carcinoma cell proliferation Inhibition of LS174T human colon carcinoma cell proliferation	[PMID: 12190313]
LX-1	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of LX-1 human lung carcinoma proliferation Inhibition of LX-1 human lung carcinoma proliferation	[PMID: 12190313]
M109	IC₅₀	0.08 μM Compound: Flavopiridol	Inhibition of M109 mouse lung carcinoma cell proliferation Inhibition of M109 mouse lung carcinoma cell proliferation	[PMID: 12190313]
MCF7	GI₅₀	0.092 μM Compound: Flavopiridol	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 33581551]
MCF7	IC₅₀	0.026 μM Compound: 1	Antiproliferative activity against MCF7 cells Antiproliferative activity against MCF7 cells	[PMID: 17123821]
MCF7	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of MCF-7 human breast carcinoma cell proliferation Inhibition of MCF-7 human breast carcinoma cell proliferation	[PMID: 12190313]
MCF7	IC₅₀	0.5 μM Compound: 1	Inhibition of MCF-7 tumor cell proliferation Inhibition of MCF-7 tumor cell proliferation	[PMID: 10843211]
MCF7	IC₅₀	0.71 μM Compound: Flavopiridol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-231	IC₅₀	0.06 μM Compound: Flavopiridol	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-468	GI₅₀	0.096 μM Compound: Flavopiridol	Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	GI₅₀	0.078 μM Compound: Flavopiridol	Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	IC₅₀	320 nM Compound: Alvocidib	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
MIA PaCa-2	IC₅₀	36 μM Compound: 1 (flavopiridol)	Inhibition of Mia PaCa-2 cell clonogenic assay Inhibition of Mia PaCa-2 cell clonogenic assay	[PMID: 11063609]
MIP	IC₅₀	0.12 μM Compound: Flavopiridol	Inhibition of MIP human colon carcinoma cell line Inhibition of MIP human colon carcinoma cell line	[PMID: 12190313]
MLF	IC₅₀	0.072 μM Compound: Flavopiridol	Inhibition of MLF mouse lung fibroblast cell proliferation Inhibition of MLF mouse lung fibroblast cell proliferation	[PMID: 12190313]
MOLM-13	IC₅₀	0.07 μM Compound: Flavopiridol	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MRC5	GI₅₀	0.028 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.039 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.049 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 23301767]
MT4	EC₅₀	0.015 μM Compound: FVP	Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay	[PMID: 25914804]
MT4	IC₅₀	0.067 μM Compound: FVP	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 25914804]
MV4-11	IC₅₀	0.079 μM Compound: 1	Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay	[PMID: 34415148]
NCI-N87	IC₅₀	111 nM Compound: Alvocidib	Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
Oocyte	IC₅₀	0.2 μM Compound: Flavopiridol	Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes	[PMID: 12593668]
Oocyte	IC₅₀	0.4 μM Compound: Flavopiridol (table 2 Page 6846)	Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes	[PMID: 16250643]
OVCAR-3	IC₅₀	0.054 μM Compound: Flavopiridol	Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation	[PMID: 12190313]
PC-3	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of PC3 human prostate carcinoma cell proliferation Inhibition of PC3 human prostate carcinoma cell proliferation	[PMID: 12190313]
PC-3	IC₅₀	10 μM Compound: 1 (flavopiridol)	Inhibition of PC3 cell clonogenic assay Inhibition of PC3 cell clonogenic assay	[PMID: 11063609]
PC-3	IC₅₀	110 nM Compound: Alvocidib	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
RPMI-8226	IC₅₀	140 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay	[PMID: 19169685]
RPMI-8226	IC₅₀	394 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay	[PMID: 19169685]
SEM	EC₅₀	0.2043 μM Compound: 4	Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Sf21	IC₅₀	395 nM Compound: 8; Alvocidib	Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate	[PMID: 27171036]
Sf9	IC₅₀	0.012 μM Compound: flavopiridol	Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells	[PMID: 17904366]
Sf9	IC₅₀	0.13 μM Compound: FVP	Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography	[PMID: 25914804]
Sf9	IC₅₀	2.5 nM Compound: 8; Alvocidib	Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis	[PMID: 27171036]
SK-BR-3	IC₅₀	0.077 μM Compound: Flavopiridol	Inhibition of SKBR-3 human breast carcinoma cell proliferation Inhibition of SKBR-3 human breast carcinoma cell proliferation	[PMID: 12190313]
SK-BR-3	IC₅₀	75 nM Compound: Alvocidib	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SK-OV-3	IC₅₀	0.22 μM Compound: Alvocidib	Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SUP-B15	EC₅₀	>86.2069 μM Compound: 4	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
T-cell	IC₅₀	20 nM Compound: 1; L868275	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 35485642]
T-cell	IC₅₀	6 nM Compound: Flavopiridol	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 19169685]
UoC-B1	EC₅₀	0.2084 μM Compound: 4	Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]

In Vitro

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases^[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol^[2].
Flavopiridol (Alvocidib) also inhibits cyclin E1 and induces apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité

In Vitro:

DMSO : 33.33 mg/mL (82.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4886 mL	12.4428 mL	24.8855 mL
5 mM	0.4977 mL	2.4886 mL	4.9771 mL
10 mM	0.2489 mL	1.2443 mL	2.4886 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (stored under nitrogen). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

Pureté et documentation

Purity: 99.70%

Fiche technique (281 KB) SDS (394 KB)

COA (255 KB) LCMS (406 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. [Content Brief]

[2]. Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. [Content Brief]

[3]. Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. [Content Brief]

[4]. Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17(1):85. [Content Brief]

Você também pode estar interessado nos seguintes produtos:

Referência

Descrição

Cond.

Price Bef. VAT

HY-15816-5mg

Ulixertinib [869886-67-9]

5mg

HY-32341-1mg

Seocalcitol [134404-52-7]

1mg

HY-10218-5mg

Everolimus [159351-69-6]

5mg

Flavopiridol [146426-40-6]

Referência HY-10005-5mg

Contactar o distribuidor local :

Marca : MedChemExpress

Contactar o distribuidor local :

Flavopiridol Related Antibodies

Você também pode estar interessado nos seguintes produtos: